FDA Grants Accelerated Approval to Iberdomide for Relapsed/Refractory Multiple Myeloma

The FDA has granted accelerated approval to iberdomide as a combination therapy for adults with relapsed/refractory multiple myeloma who have received at least one prior line of therapy. This marks the first approval of a cereblon E3 ligase modulator (CELMoD) for this condition and is notable as the first myeloma approval based primarily on measurable residual disease (MRD) data from the Phase 3 EXCALIBER-RRMM trial.